Literature DB >> 18768899

Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.

Shanli Tsui1, Vibha Naik, Neil Hoa, Catherine J Hwang, Nikoo F Afifiyan, Amiya Sinha Hikim, Andrew G Gianoukakis, Raymond S Douglas, Terry J Smith.   

Abstract

Thyroid-stimulating hormone receptor (TSHR) plays a central role in regulating thyroid function and is targeted by IgGs in Graves' disease (GD-IgG). Whether TSHR is involved in the pathogenesis of thyroid-associated ophthalmopathy (TAO), the orbital manifestation of GD, remains uncertain. TSHR signaling overlaps with that of insulin-like grow factor 1 receptor (IGF-1R). GD-IgG can activate fibroblasts derived from donors with GD to synthesize T cell chemoattractants and hyaluronan, actions mediated through IGF-1R. In this study, we compare levels of IGF-1R and TSHR on the surfaces of TAO and control orbital fibroblasts and thyrocytes and explore the physical and functional relationship between the two receptors. TSHR levels are 11-fold higher on thyrocytes than on TAO or control fibroblasts. In contrast, IGF-1R levels are 3-fold higher on TAO vs control fibroblasts. In pull-down studies using fibroblasts, thyrocytes, and thyroid tissue, Abs directed specifically against either IGF-1Rbeta or TSHR bring both proteins out of solution. Moreover, IGF-1Rbeta and TSHR colocalize to the perinuclear and cytoplasmic compartments in fibroblasts and thyrocytes by confocal microscopy. Examination of orbital tissue from patients with TAO reveals similar colocalization to cell membranes. Treatment of primary thyrocytes with recombinant human TSH results in rapid ERK phosphorylation which can be blocked by an IGF-1R-blocking mAb. Our findings suggest that IGF-1R might mediate some TSH-provoked signaling. Furthermore, they indicate that TSHR levels on orbital fibroblasts are considerably lower than those on thyrocytes and that this receptor associates with IGF-1R in situ and together may comprise a functional complex in thyroid and orbital tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768899      PMCID: PMC2775538          DOI: 10.4049/jimmunol.181.6.4397

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

1.  The basolateral sorting signals of the thyrotropin and luteinizing hormone receptors: an unusual family of signals sharing an unusual distal intracellular localization, but unrelated in their structures.

Authors:  Isabelle Beau; Marie-Thérèse Groyer-Picard; Agnès Desroches; Eric Condamine; Jérôme Leprince; Jean-Philippe Tomé; Philippe Dessen; Hubert Vaudry; Micheline Misrahi
Journal:  Mol Endocrinol       Date:  2003-12-23

2.  Key apoptotic pathways for heat-induced programmed germ cell death in the testis.

Authors:  Amiya P Sinha Hikim; Yanhe Lue; Cindy M Yamamoto; Yanira Vera; Susana Rodriguez; Pauline H Yen; Kevin Soeng; Christina Wang; Ronald S Swerdloff
Journal:  Endocrinology       Date:  2003-07       Impact factor: 4.736

3.  Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.

Authors:  Terry J Smith; Neil Hoa
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

4.  The role of adenosine 3',5'-monophosphate in the regulation of receptors for thyrotropin and insulin-like growth factor I in the FRTL5 rat thyroid follicular cell.

Authors:  D Tramontano; A C Moses; S H Ingbar
Journal:  Endocrinology       Date:  1988-01       Impact factor: 4.736

5.  Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells.

Authors:  E S Park; H Kim; J M Suh; S J Park; O Y Kwon; Y K Kim; H K Ro; B Y Cho; J Chung; M Shong
Journal:  Mol Endocrinol       Date:  2000-03

6.  Adenosine 3',5'-monophosphate mediates both the mitogenic effect of thyrotropin and its ability to amplify the response to insulin-like growth factor I in FRTL5 cells.

Authors:  D Tramontano; A C Moses; B M Veneziani; S H Ingbar
Journal:  Endocrinology       Date:  1988-01       Impact factor: 4.736

7.  Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Authors:  M N Gerding; J W van der Meer; M Broenink; O Bakker; W M Wiersinga; M F Prummel
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

8.  Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors:  Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

9.  Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors.

Authors:  Dennis K Lee; A José Lança; Regina Cheng; Tuan Nguyen; Xiao Dong Ji; Fernand Gobeil; Sylvain Chemtob; Susan R George; Brian F O'Dowd
Journal:  J Biol Chem       Date:  2003-11-26       Impact factor: 5.157

10.  Characterization and regulations of the receptor for insulin-like growth factor-I in the FRTL-5 rat thyroid follicular cell line.

Authors:  D Tramontano; A C Moses; R Picone; S H Ingbar
Journal:  Endocrinology       Date:  1987-02       Impact factor: 4.736

View more
  111 in total

Review 1.  Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

2.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

Review 4.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

5.  Disrupted TSH Receptor Expression in Female Mouse Lung Fibroblasts Alters Subcellular IGF-1 Receptor Distribution.

Authors:  Stephen J Atkins; Stephen I Lentz; Roshini Fernando; Terry J Smith
Journal:  Endocrinology       Date:  2015-09-21       Impact factor: 4.736

6.  Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.

Authors:  Kai-Chun Cheng; Yu-Jen Wu; Kai-Hung Cheng; Kai-Yuan Cheng; Kuo-Jen Chen; Wen-Chuan Wu; Po-Yen Lee; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

7.  Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB.

Authors:  Erin F Gillespie; Nupur Raychaudhuri; Konstantinos I Papageorgiou; Stephen J Atkins; Ying Lu; Laya K Charara; Tünde Mester; Terry J Smith; Raymond S Douglas
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-21       Impact factor: 4.799

Review 8.  TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Authors:  Christine C Krieger; Susanne Neumann; Marvin C Gershengorn
Journal:  Pharmacol Ther       Date:  2020-02-13       Impact factor: 12.310

9.  Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Authors:  Christine C Krieger; Susanne Neumann; Robert F Place; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  J Clin Endocrinol Metab       Date:  2014-12-08       Impact factor: 5.958

10.  Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.

Authors:  Hao Wang; Stephen J Atkins; Roshini Fernando; Rui-Li Wei; Terry J Smith
Journal:  Endocrinology       Date:  2015-08-19       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.